IKS Health has released its investor presentation for the second quarter of fiscal year 2027, covering the period ended September 30, 2026. The presentation details the company’s financial performance, including significant growth in revenue and adjusted EBITDA. It also outlines IKS Health’s strategic pillars, operational achievements, key deal wins, and future outlook, providing a comprehensive update for stakeholders.
IKS Health Unveils Q2 FY27 Investor Presentation
IKS Health has provided its investor presentation for the second quarter of fiscal year 2027, detailing financial results for the quarter and half-year ended September 30, 2026. This release offers stakeholders a comprehensive overview of the company’s performance, strategic initiatives, and market position.
Key Financial Highlights
The presentation highlights robust financial performance, with revenue from operations reaching INR 15,925 million, marking a 103.9% YoY growth in INR and 87.3% YoY growth in USD. EBITDA stood at INR 4,415 million, up 62.5% YoY, while Adjusted EBITDA grew 63.2% YoY to INR 4,591 million. Profit After Tax (PAT) saw a 20.4% YoY increase to INR 2,176 million, with Adjusted PAT rising 36.0% YoY to INR 2,734 million.
Strategic Pillars and Operational Updates
IKS Health’s strategy is built on five key pillars: Integrated System of Action (SOA) & System of Record (SOR) for the rural/community health system market, proprietary models for the large medical group market, driving growth through re-stratified key levers, optimizing margins through operating model transformation, and fostering a strong culture and leadership. The company emphasizes its role as a comprehensive healthcare enablement platform, empowering provider organizations with AI-native solutions.
Market Position and Client Relationships
The presentation underscores IKS Health’s significant market presence, with a Total Addressable Market (TAM) of US$5tn in US Healthcare Expenditure and a TAM/Outsourced Market of US$260bn/US$34bn. The company boasts 1,900+ healthcare organizations as clients and maintains 90%+ revenues from repeat customers. Client relationships are deep, with an average vintage of 5+ years for top clients.
Key Deal Wins and Consolidation of TruBridge
Significant deal wins include partnerships with White-Wilson Medical Center for RCM optimization, UMass Memorial Health for data migration, and Evolve Orthopedic Partners for end-to-end RCM services. The consolidation of TruBridge over 82 days is a notable operational highlight, contributing to strong revenue and margin profiles. The company also reports a globally diversified workforce of 16,318 employees.
Focus on Cash Generation and Shareholder Value
IKS Health demonstrates continued strong cash generation, with Operating Cash Flow (OCF) and Free Cash Flow (FCF) showing positive trends. The company also reports improving Earnings Per Share (EPS) and maintains a high Return on Equity (ROE), indicating a commitment to shareholder value creation.
Source: BSE
